Oxidized low-density lipoprotein neoepitopes (OxLDL neoepitopes)

Oxidized low-density lipoprotein (OxLDL) neoepitopes are unique structural modifications that arise on LDL particles following oxidative stress, primarily involving the lipid and protein (Apolipoprotein B-100) components. These neoepitopes, such as malondialdehyde (MDA) adducts and phosphocholine groups, are recognized by the innate immune system as damage-associated molecular patterns (DAMPs) through scavenger receptors and natural antibodies (e.g., PubMed: 23446712). They play a central role in the pathogenesis of atherosclerosis by triggering the recruitment of inflammatory cells and promoting the transformation of macrophages into foam cells within the vascular wall (NIH: PMC3415605). In a therapeutic context, OxLDL neoepitopes are targeted to mitigate the chronic inflammation that drives cardiovascular disease. Experimental treatments include monoclonal antibodies like BI-204, which binds to specific MDA-modified sequences of ApoB-100 to prevent plaque progression, and vaccine candidates like CVX-210 designed to induce protective immune responses (PubMed: 22438459). By neutralizing these epitopes, researchers aim to stabilize existing plaques and reduce the risk of acute cardiovascular events. The presence of these neoepitopes also serves as a significant biomarker for oxidative stress and cardiovascular risk assessment in clinical settings.

Other names

Oxidation-specific epitopesOSEsOxidized LDL epitopesMalondialdehyde-modified LDL epitopesMDA-LDL neoepitopesPhosphocholine-containing neoepitopes

Monoclonal antibodies or vaccines target these neoepitopes to neutralize pro-inflammatory signaling, inhibit the uptake of oxidized lipids by macrophages (preventing foam cell formation), and promote the clearance of modified LDL particles from the circulation and arterial wall.